Takeda/Lilly Actos May Not Have Adverse Lipid Profile Of Other "Glitazones"
Executive Summary
Takeda's Actos (pioglitazone) does not have the adverse effect on lipids that other type 2 diabetes drugs in its class have, the company told the Endocrine & Metabolic Drugs Advisory Committee April 23.